| CASE REPORT |
|
| Ahead of Print |
|
|
Rosuvastatin-induced rhabdomyolysis: A case report
Ravindra Nikalji1, Suvadeep Sen2
1 Department of Nephrology, Apollo Hospital, Navi Mumbai, Maharashtra, India
2 Department of Critical Care, Apollo Hospital, Navi Mumbai, Maharashtra, India
Correspondence Address:
Suvadeep Sen,
Department of Critical Care, Apollo Hospital, Plot No- 23, CBD Belapur, Navi Mumbai, - 400 614, Maharashtra
India
 Source of Support: None, Conflict of Interest: None DOI: 10.4103/ijn.IJN_388_19
|
|
|
Rosuvastatin is a recently approved statin and used widely across the globe for primary and secondary prevention of atherosclerotic cardiovascular heart disease. It has the highest lipid-lowering property among all statins and relatively well tolerated. Rhabdomyolysis is a rare but potentially serious adverse effect. The present report highlights the case of a patient admitted with proximal myopathy with severe rhabdomyolysis and acute kidney injury associated with life-threatening hyperkalemia. The symptoms appeared within 1 month of starting rosuvastatin. He required temporary dialysis to overcome the crisis. His myopathy and kidney injury were completely reversible after a few months of stopping the drug. In this report, we have also discussed the various risk factors for developing myopathy with statins and the importance of strict pharmacovigilance, and a greater caution among physicians while using this drug.
|
|
|
|
|
|
|
|
Editorial Board
Search Pubmed for
